SCHEMBL29509474

SCHEMBL29509474

O=[N+]([O-])c1cccc(C(F)F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.47
GPR35 Q9HC97 2/20 0.45
ALDH1A1 P00352 4/20 0.41
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 4/20 0.41
S100A4 P26447 2/20 0.41
PTPRC P08575 1/20 0.41
HSD17B10 Q99714 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
HSPB1 P04792 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16797211 1.00 TDP1 (0.47) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL9004049 0.83 TDP1 (0.48) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL16119496 0.83 CYP1A2 (0.47) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL28909321 0.83 TDP1 (0.45) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL10686074 0.82 CYP1A2 (0.53) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL29746197 0.82 CYP1A2 (0.53) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL3010961 0.81 TDP1 (0.61) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL7858061 0.80 TDP1 (0.46) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL16951733 0.80 TDP1 (0.46) TDP1GPR35ALDH1A1TSHRSMN1; SMN2
SCHEMBL27841207 0.80 TDP1 (0.46) TDP1GPR35ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 EP disclosed
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 EP disclosed
EP-4562004-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2025-06-04 EP disclosed
CN-119585258-A Novel 7-substituted indole sulfonamide derivatives 豪夫迈·罗氏有限公司 2025-03-07 CN disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 WO disclosed
CN-118974035-A 2-Aminoimidazole derivatives as PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-11-15 CN disclosed
WO-2024233900-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-11-14 WO disclosed
WO-2024023129-A1 NOVEL 7-SUBSTITUTED INDOLE SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2024-02-01 WO disclosed
CN-112292375-B Substituted alkoxypyridinyl indole sulfonamides 优时比制药有限公司 2023-12-05 CN disclosed
EP-3793994-B1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2023-08-23 EP disclosed
WO-2022266458-A1 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
CN-108064224-B Amide-substituted thiazoles as modulators of Ror gamma t 詹森药业有限公司 2022-03-29 CN disclosed